- Home
- GSIW vs RDHL Comparison
GSIW vs RDHL Comparison
Compare GSIW & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GSIW | RDHL |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2M | 4.0M |
| IPO Year | 2022 | 2012 |
Fundamental Metrics
Financial Performance| Metric | GSIW | RDHL |
|---|---|---|
| Price | $16.03 | $0.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.9K | ★ 2.4M |
| Earning Date | 08-04-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.05 | $0.57 |
| 52 Week High | $38.55 | $2.79 |
Technical Indicators
Market Signals| Indicator | GSIW | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 38.18 | 53.24 |
| Support Level | $14.84 | $0.62 |
| Resistance Level | $18.24 | $0.85 |
| Average True Range (ATR) | 1.60 | 0.10 |
| MACD | 0.39 | 0.01 |
| Stochastic Oscillator | 39.38 | 13.86 |
Price Performance
Historical ComparisonAbout GSIW Garden Stage Limited
Garden Stage Ltd, through its subsidiaries is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; asset management services; investment advisory services; due diligence services; and introduction and referral services. The company operates in a single segment and derives all of its revenue from Hong Kong.
About RDHL Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.